 |
|
| PROGRAM | THERAPEUTIC AREA | PRECLINICAL | PHASE I | PHASE II | PIVOTAL/ PHASE III |
APPROVED (U.S.) |
| ADCETRIS™ (brentuximab vedotin) |  | | | | |
| Brentuximab Vedotin | Post-transplant HL relapse prevention (AETHERA trial) | | | | | ||
| Relapsed/refractory CD30-positive non-Hodgkin lymphomas | | | | ||||
| CD30-positive non-lymphoma malignancies | | | | ||||
| Retreatment of hematologic malignancies | | | | ||||
| Front-line HL (+chemotherapy) | | | |||||
| Front-line CD30+ mature T-cell malignancies (+chemotherapy) | | |
| SGN-75 | CD70+ renal cell carcinoma and non-Hodgkin lymphoma | | |
| ASG-5ME | Pancreatic cancer | | | ||||
| Prostate cancer | | |
| ASG-22ME | Solid tumors | | |
| SGN-CD19A | CD19+ hematologic malignancies | |
| ADC Collaborations | 12 clinical-stage ADC programs in hematologic malignancies and solid tumors |  | | |
| Antibody-drug conjugate | ADC collaborator programs |